ENZY Stock Overview
A life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Enzymatica AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 2.00 |
52 Week High | SEK 4.43 |
52 Week Low | SEK 1.93 |
Beta | -0.0091 |
11 Month Change | -19.35% |
3 Month Change | -42.03% |
1 Year Change | -30.43% |
33 Year Change | -81.65% |
5 Year Change | -58.51% |
Change since IPO | -72.97% |
Recent News & Updates
Recent updates
Is Enzymatica (STO:ENZY) Using Too Much Debt?
Jul 20Is Enzymatica (STO:ENZY) Using Too Much Debt?
Jul 22Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?
Feb 18Estimating The Fair Value Of Enzymatica AB (STO:ENZY)
Jan 12Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade
Jul 20Revenue Downgrade: Here's What Analysts Forecast For Enzymatica AB (STO:ENZY)
May 02Shareholder Returns
ENZY | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | -24.8% | -2.6% | -1.8% |
1Y | -30.4% | 75.7% | 14.4% |
Return vs Industry: ENZY underperformed the Swedish Pharmaceuticals industry which returned 75.3% over the past year.
Return vs Market: ENZY underperformed the Swedish Market which returned 14.4% over the past year.
Price Volatility
ENZY volatility | |
---|---|
ENZY Average Weekly Movement | 12.3% |
Pharmaceuticals Industry Average Movement | 11.8% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.6% |
10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: ENZY's share price has been volatile over the past 3 months.
Volatility Over Time: ENZY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 16 | Claus Egstrand | www.enzymatica.se |
Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care.
Enzymatica AB (publ) Fundamentals Summary
ENZY fundamental statistics | |
---|---|
Market cap | SEK 346.76m |
Earnings (TTM) | -SEK 55.95m |
Revenue (TTM) | SEK 44.95m |
7.7x
P/S Ratio-6.2x
P/E RatioIs ENZY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ENZY income statement (TTM) | |
---|---|
Revenue | SEK 44.95m |
Cost of Revenue | SEK 16.19m |
Gross Profit | SEK 28.76m |
Other Expenses | SEK 84.72m |
Earnings | -SEK 55.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
Earnings per share (EPS) | -0.32 |
Gross Margin | 63.99% |
Net Profit Margin | -124.47% |
Debt/Equity Ratio | 38.7% |
How did ENZY perform over the long term?
See historical performance and comparison